{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:21:22Z","timestamp":1787988082332,"version":"build-2784847793"},"update-to":[{"DOI":"10.1371\/journal.ppat.1007772","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T00:00:00Z","timestamp":1559174400000}}],"reference-count":67,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T00:00:00Z","timestamp":1558051200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U19-AI123862, R21-AI26582, R01-AI132213,"],"award-info":[{"award-number":["U19-AI123862, R21-AI26582, R01-AI132213,"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U19-AI123862"],"award-info":[{"award-number":["U19-AI123862"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21-AI126582, R01-AI132213"],"award-info":[{"award-number":["R21-AI126582, R01-AI132213"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["222887, 1016351, 1043067"],"award-info":[{"award-number":["222887, 1016351, 1043067"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1084706"],"award-info":[{"award-number":["APP1084706"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["AdG2014-HEPCIR, FP7 HepaMab and Interreg IVFEDER-Hepato-Regio-Net 2012"],"award-info":[{"award-number":["AdG2014-HEPCIR, FP7 HepaMab and Interreg IVFEDER-Hepato-Regio-Net 2012"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32-AI125186"],"award-info":[{"award-number":["T32-AI125186"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004836","name":"Danish Council for Independent Research","doi-asserted-by":"crossref","award":["DFF-4004-00598"],"award-info":[{"award-number":["DFF-4004-00598"]}],"id":[{"id":"10.13039\/501100004836","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["NNF17OC0029372"],"award-info":[{"award-number":["NNF17OC0029372"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plospathogens.org"],"crossmark-restriction":false},"short-container-title":["PLoS Pathog"],"DOI":"10.1371\/journal.ppat.1007772","type":"journal-article","created":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T13:30:33Z","timestamp":1558099833000},"page":"e1007772","update-policy":"https:\/\/doi.org\/10.1371\/journal.ppat.corrections_policy","source":"Crossref","is-referenced-by-count":59,"title":["Broadly neutralizing antibodies from an individual that naturally cleared multiple hepatitis C virus infections uncover molecular determinants for E2 targeting and vaccine design"],"prefix":"10.1371","volume":"15","author":[{"given":"Zhen-Yong","family":"Keck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian G.","family":"Pierce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7971-6906","authenticated-orcid":true,"given":"Alexander","family":"Underwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9844-3744","authenticated-orcid":true,"given":"Rowena A.","family":"Bull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2203-9478","authenticated-orcid":true,"given":"Jannick","family":"Prentoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9865-152X","authenticated-orcid":true,"given":"Rodrigo","family":"Vel\u00e1zquez-Moctezuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie R.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Luciani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnathan D.","family":"Guest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4364-5127","authenticated-orcid":true,"given":"Catherine","family":"Fauvelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas F.","family":"Baumert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7815-4806","authenticated-orcid":true,"given":"Jens","family":"Bukh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew R.","family":"Lloyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7149-6160","authenticated-orcid":true,"given":"Steven K. H.","family":"Foung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2019,5,17]]},"reference":[{"issue":"4","key":"ref1","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/hep.26141","article-title":"Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence","volume":"57","author":"K Mohd Hanafiah","year":"2013","journal-title":"Hepatology"},{"key":"ref2","unstructured":"WHO. Global hepatitis report, 2017. 2017:83. Epub April 2017."},{"issue":"20","key":"ref3","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1056\/NEJMra1213651","article-title":"Current and future therapies for hepatitis C virus infection","volume":"368","author":"TJ Liang","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"ref4","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.jhep.2016.07.035","article-title":"The history of hepatitis C virus (HCV): Basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control","volume":"65","author":"J. Bukh","year":"2016","journal-title":"J Hepatol"},{"issue":"9","key":"ref5","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/S1473-3099(16)30005-6","article-title":"Access to treatment for hepatitis C virus infection: time to put patients first","volume":"16","author":"BR Edlin","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"ref6","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/hep.26639","article-title":"The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection","volume":"59","author":"J Grebely","year":"2014","journal-title":"Hepatology"},{"issue":"14","key":"ref7","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.1073\/pnas.0607026104","article-title":"Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C","volume":"104","author":"JM Pestka","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"ref8","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1002\/hep.27013","article-title":"Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses","volume":"59","author":"WO Osburn","year":"2014","journal-title":"Hepatology"},{"issue":"10","key":"ref9","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1111\/add.12643","article-title":"A prospective study of hepatitis C incidence in Australian prisoners","volume":"109","author":"F Luciani","year":"2014","journal-title":"Addiction"},{"issue":"7262","key":"ref10","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature08309","article-title":"Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance","volume":"461","author":"D Ge","year":"2009","journal-title":"Nature"},{"issue":"4","key":"ref11","doi-asserted-by":"crossref","first-page":"e1002653","DOI":"10.1371\/journal.ppat.1002653","article-title":"Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate","volume":"8","author":"ZY Keck","year":"2012","journal-title":"PLoS Pathog"},{"issue":"1","key":"ref12","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1128\/JVI.01941-12","article-title":"Cooperativity in virus neutralization by human monoclonal antibodies to two adjacent regions located at the amino terminus of hepatitis C virus E2 glycoprotein","volume":"87","author":"Z Keck","year":"2013","journal-title":"J Virol"},{"issue":"12","key":"ref13","doi-asserted-by":"crossref","first-page":"6061","DOI":"10.1128\/JVI.02475-07","article-title":"Definition of a conserved immunodominant domain on hepatitis C virus E2 glycoprotein by neutralizing human monoclonal antibodies","volume":"82","author":"ZY Keck","year":"2008","journal-title":"J Virol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/978-1-4939-8976-8_29","article-title":"In Vitro Neutralization Assay Using Cultured Hepatitis C Virus.","volume":"1911","author":"J Prentoe","year":"2019","journal-title":"Methods Mol Biol"},{"issue":"5734","key":"ref15","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1126\/science.1114016","article-title":"Complete replication of hepatitis C virus in cell culture","volume":"309","author":"BD Lindenbach","year":"2005","journal-title":"Science"},{"issue":"3","key":"ref16","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1073\/pnas.0711044105","article-title":"Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization","volume":"105","author":"TK Scheel","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"ref17","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/hep.22673","article-title":"Development and characterization of hepatitis C virus genotype 1\u20137 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs","volume":"49","author":"JM Gottwein","year":"2009","journal-title":"Hepatology"},{"issue":"6","key":"ref18","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1128\/JVI.01605-10","article-title":"Efficient culture adaptation of hepatitis C virus recombinants with genotype-specific core-NS2 by using previously identified mutations","volume":"85","author":"TK Scheel","year":"2011","journal-title":"J Virol"},{"issue":"12","key":"ref19","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1086\/593021","article-title":"Highly efficient JFH1-based cell-culture system for hepatitis C virus genotype 5a: failure of homologous neutralizing-antibody treatment to control infection","volume":"198","author":"TB Jensen","year":"2008","journal-title":"J Infect Dis"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.antiviral.2018.07.014","article-title":"Current status and future development of infectious cell-culture models for the major genotypes of hepatitis C virus: Essential tools in testing of antivirals and emerging vaccine strategies","volume":"158","author":"S Ramirez","year":"2018","journal-title":"Antiviral Res"},{"issue":"5","key":"ref21","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1128\/JVI.01594-10","article-title":"Hypervariable region 1 differentially impacts viability of hepatitis C virus strains of genotypes 1 to 6 and impairs virus neutralization","volume":"85","author":"J Prentoe","year":"2011","journal-title":"J Virol"},{"issue":"5","key":"ref22","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1002\/hep.26524","article-title":"Neutralization resistance of hepatitis C virus can be overcome by recombinant human monoclonal antibodies","volume":"58","author":"J Pedersen","year":"2013","journal-title":"Hepatology"},{"issue":"6","key":"ref23","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1002\/hep.28705","article-title":"Hypervariable region 1 shielding of hepatitis C virus is a main contributor to genotypic differences in neutralization sensitivity","volume":"64","author":"J Prentoe","year":"2016","journal-title":"Hepatology"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.3389\/fimmu.2018.02146","article-title":"Hypervariable Region 1 in Envelope Protein 2 of Hepatitis C Virus: A Linchpin in Neutralizing Antibody Evasion and Viral Entry.","volume":"9","author":"J Prentoe","year":"2018","journal-title":"Front Immunol"},{"issue":"2","key":"ref25","doi-asserted-by":"crossref","first-page":"e1006214","DOI":"10.1371\/journal.ppat.1006214","article-title":"Applying antibody-sensitive hypervariable region 1-deleted hepatitis C virus to the study of escape pathways of neutralizing human monoclonal antibody AR5A","volume":"13","author":"R Velazquez-Moctezuma","year":"2017","journal-title":"PLoS Pathog"},{"issue":"100","key":"ref26","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.antiviral.2014.02.013","article-title":"The past, present and future of neutralizing antibodies for hepatitis C virus","volume":"105","author":"JK Ball","year":"2014","journal-title":"Antiviral Res"},{"issue":"17","key":"ref27","doi-asserted-by":"crossref","first-page":"9224","DOI":"10.1128\/JVI.78.17.9224-9232.2004","article-title":"Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct properties and biological functions","volume":"78","author":"ZY Keck","year":"2004","journal-title":"J Virol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.3389\/fimmu.2018.01194","article-title":"Mapping Determinants of Virus Neutralization and Viral Escape for Rational Design of a Hepatitis C Virus Vaccine.","volume":"9","author":"ML Keck","year":"2018","journal-title":"Front Immunol"},{"key":"ref29","article-title":"Global mapping of antibody recognition of the hepatitis C virus E2 glycoprotein: Implications for vaccine design","author":"BG Pierce","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"ref30","doi-asserted-by":"crossref","first-page":"e1006735","DOI":"10.1371\/journal.ppat.1006735","article-title":"Probing the antigenicity of hepatitis C virus envelope glycoprotein complex by high-throughput mutagenesis","volume":"13","author":"R Gopal","year":"2017","journal-title":"PLoS Pathog"},{"issue":"4","key":"ref31","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01909-18","article-title":"Hepatitis C Virus Escape Studies of Human Antibody AR3A Reveal a High Barrier to Resistance and Novel Insights on Viral Antibody Evasion Mechanisms","volume":"93","author":"R Velazquez-Moctezuma","year":"2019","journal-title":"J Virol"},{"issue":"16","key":"ref32","doi-asserted-by":"crossref","first-page":"6205","DOI":"10.1073\/pnas.1114927109","article-title":"Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus","volume":"109","author":"E Giang","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"ref33","doi-asserted-by":"crossref","first-page":"e1004128","DOI":"10.1371\/journal.ppat.1004128","article-title":"Hepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agents","volume":"10","author":"F Xiao","year":"2014","journal-title":"PLoS Pathog"},{"issue":"24","key":"ref34","doi-asserted-by":"crossref","first-page":"13297","DOI":"10.1128\/JVI.01708-13","article-title":"Characterization of hepatitis C virus intra- and intergenotypic chimeras reveals a role of the glycoproteins in virus envelopment","volume":"87","author":"E Steinmann","year":"2013","journal-title":"J Virol"},{"issue":"22","key":"ref35","doi-asserted-by":"crossref","first-page":"10407","DOI":"10.1128\/JVI.74.22.10407-10416.2000","article-title":"Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes","volume":"74","author":"KG Hadlock","year":"2000","journal-title":"J Virol"},{"issue":"1","key":"ref36","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nm1698","article-title":"Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge","volume":"14","author":"M Law","year":"2008","journal-title":"Nat Med"},{"issue":"10","key":"ref37","doi-asserted-by":"crossref","first-page":"e0165047","DOI":"10.1371\/journal.pone.0165047","article-title":"Hepatitis C virus Broadly Neutralizing Monoclonal Antibodies Isolated 25 Years after Spontaneous Clearance","volume":"11","author":"SJ Merat","year":"2016","journal-title":"PLoS One"},{"issue":"9","key":"ref38","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.92872","article-title":"Broadly neutralizing antibodies with few somatic mutations and hepatitis C virus clearance","volume":"2","author":"JR Bailey","year":"2017","journal-title":"JCI Insight"},{"issue":"4","key":"ref39","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1182\/blood.V97.4.1023","article-title":"V(H)1-69 gene is preferentially used by hepatitis C virus-associated B cell lymphomas and by normal B cells responding to the E2 viral antigen","volume":"97","author":"CH Chan","year":"2001","journal-title":"Blood"},{"issue":"1","key":"ref40","doi-asserted-by":"crossref","first-page":"eaav1882","DOI":"10.1126\/sciadv.aav1882","article-title":"Genetic and structural insights into broad neutralization of hepatitis C virus by human VH1-69 antibodies","volume":"5","author":"N Tzarum","year":"2019","journal-title":"Sci Adv"},{"issue":"12","key":"ref41","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1016\/j.celrep.2017.08.084","article-title":"Antibody 27F3 Broadly Targets Influenza A Group 1 and 2 Hemagglutinins through a Further Variation in VH1-69 Antibody Orientation on the HA Stem","volume":"20","author":"S Lang","year":"2017","journal-title":"Cell Rep"},{"issue":"6162","key":"ref42","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1126\/science.1243876","article-title":"Hepatitis C virus E2 envelope glycoprotein core structure","volume":"342","author":"L Kong","year":"2013","journal-title":"Science"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"D432","DOI":"10.1093\/nar\/gku1106","article-title":"PyIgClassify: a database of antibody CDR structural classifications","volume":"43","author":"J Adolf-Bryfogle","year":"2015","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"ref44","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nsmb.1566","article-title":"Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses","volume":"16","author":"J Sui","year":"2009","journal-title":"Nat Struct Mol Biol"},{"issue":"19","key":"ref45","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1038\/emboj.2008.179","article-title":"Germline V-genes sculpt the binding site of a family of antibodies neutralizing human cytomegalovirus","volume":"27","author":"CA Thomson","year":"2008","journal-title":"The EMBO journal"},{"issue":"Pt 11","key":"ref46","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1099\/vir.0.83065-0","article-title":"Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33","volume":"88","author":"AW Tarr","year":"2007","journal-title":"J Gen Virol"},{"issue":"18","key":"ref47","doi-asserted-by":"crossref","first-page":"7537","DOI":"10.1073\/pnas.0902749106","article-title":"Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity","volume":"106","author":"P Zhang","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"ref48","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/bioinformatics\/bth485","article-title":"The Los Alamos hepatitis C sequence database","volume":"21","author":"C Kuiken","year":"2005","journal-title":"Bioinformatics"},{"issue":"19","key":"ref49","doi-asserted-by":"crossref","first-page":"5017","DOI":"10.1093\/emboj\/cdf529","article-title":"The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus","volume":"21","author":"E Scarselli","year":"2002","journal-title":"Embo J"},{"issue":"5390","key":"ref50","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1126\/science.282.5390.938","article-title":"Binding of hepatitis C virus to CD81","volume":"282","author":"P Pileri","year":"1998","journal-title":"Science"},{"issue":"3","key":"ref51","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/hep.26733","article-title":"Critical interaction between E1 and E2 glycoproteins determines binding and fusion properties of hepatitis C virus during cell entry","volume":"59","author":"F Douam","year":"2014","journal-title":"Hepatology"},{"issue":"2","key":"ref52","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.virol.2004.06.042","article-title":"Cross-reactive pseudovirus-neutralizing anti-envelope antibodies coexist with antibodies devoid of such activity in persistent hepatitis C virus infection","volume":"327","author":"R Burioni","year":"2004","journal-title":"Virology"},{"issue":"20","key":"ref53","doi-asserted-by":"crossref","first-page":"10451","DOI":"10.1128\/JVI.05259-11","article-title":"Mapping a region of hepatitis C virus E2 that is responsible for escape from neutralizing antibodies and a core CD81-binding region that does not tolerate neutralization escape mutations","volume":"85","author":"ZY Keck","year":"2011","journal-title":"J Virol"},{"issue":"3","key":"ref54","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hep.26430","article-title":"An alpaca nanobody inhibits hepatitis C virus entry and cell-to-cell transmission","volume":"58","author":"AW Tarr","year":"2013","journal-title":"Hepatology"},{"issue":"1","key":"ref55","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/infdis\/jiy481","article-title":"Hepatitis C Virus-Escape Studies for Human Monoclonal Antibody AR4A Reveal Isolate-Specific Resistance and a High Barrier to Resistance","volume":"219","author":"R Velazquez-Moctezuma","year":"2019","journal-title":"J Infect Dis"},{"issue":"5","key":"ref56","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1053\/j.gastro.2010.07.005","article-title":"A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice","volume":"139","author":"HL Tillmann","year":"2010","journal-title":"Gastroenterology"},{"issue":"5","key":"ref57","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.chom.2018.10.009","article-title":"HCV Broadly Neutralizing Antibodies Use a CDRH3 Disulfide Motif to Recognize an E2 Glycoprotein Site that Can Be Targeted for Vaccine Design.","volume":"24","author":"AI Flyak","year":"2018","journal-title":"Cell Host Microbe"},{"issue":"1","key":"ref58","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1186\/1471-2458-10-633","article-title":"Incidence of primary hepatitis C infection and risk factors for transmission in an Australian prisoner cohort.","volume":"10","author":"S Teutsch","year":"2010","journal-title":"BMC Public Health"},{"issue":"5","key":"ref59","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1002\/hep.23885","article-title":"Frequent multiple hepatitis C virus infections among injection drug users in a prison setting","volume":"52","author":"ST Pham","year":"2010","journal-title":"Hepatology"},{"issue":"4","key":"ref60","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/molbev\/mst010","article-title":"MAFFT multiple sequence alignment software version 7: improvements in performance and usability","volume":"30","author":"K Katoh","year":"2013","journal-title":"Mol Biol Evol"},{"issue":"5","key":"ref61","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1084\/jem.20021756","article-title":"Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes","volume":"197","author":"B Bartosch","year":"2003","journal-title":"J Exp Med"},{"issue":"5","key":"ref62","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/hep.27298","article-title":"Breadth of neutralization and synergy of clinically relevant human monoclonal antibodies against HCV genotypes 1a, 1b, 2a, 2b, 2c, and 3a","volume":"60","author":"TH Carlsen","year":"2014","journal-title":"Hepatology"},{"issue":"10","key":"ref63","doi-asserted-by":"crossref","first-page":"5277","DOI":"10.1128\/JVI.02667-09","article-title":"Novel infectious cDNA clones of hepatitis C virus genotype 3a (strain S52) and 4a (strain ED43): genetic analyses and in vivo pathogenesis studies","volume":"84","author":"JM Gottwein","year":"2010","journal-title":"J Virol"},{"issue":"12","key":"ref64","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1093\/bioinformatics\/btl117","article-title":"Pvclust: an R package for assessing the uncertainty in hierarchical clustering","volume":"22","author":"R Suzuki","year":"2006","journal-title":"Bioinformatics"},{"issue":"2","key":"ref65","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1093\/bioinformatics\/btg412","article-title":"APE: Analyses of Phylogenetics and Evolution in R language","volume":"20","author":"E Paradis","year":"2004","journal-title":"Bioinformatics"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"W503","DOI":"10.1093\/nar\/gkn316","article-title":"IMGT\/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis","volume":"36","author":"X Brochet","year":"2008","journal-title":"Nucleic Acids Res"},{"key":"ref67","unstructured":"Beaumont T, Merat SJL, Schinkel CJ, Molenkamp R, inventors; AIMM Therapeutics B.V., assignee. Hepatitis C virus specific antibody. US patent application 2017\/0313764 A1. November 2, 2017."}],"updated-by":[{"DOI":"10.1371\/journal.ppat.1007772","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T00:00:00Z","timestamp":1559174400000}}],"container-title":["PLOS Pathogens"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.ppat.1007772","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T19:15:28Z","timestamp":1588965328000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1007772"}},"subtitle":[],"editor":[{"given":"F\u00e9lix A.","family":"Rey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,5,17]]},"references-count":67,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,5,17]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.ppat.1007772","relation":{"new_version":[{"id-type":"doi","id":"10.1371\/journal.ppat.1007772","asserted-by":"object"}]},"ISSN":["1553-7374"],"issn-type":[{"value":"1553-7374","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,17]]}}}